Suffering succotash - do you believe the nerve of these scientists professing the antithesis of insulin-dependent diabetes!! Scientist have proven that supplementation of Gymnema sylvestre appears to enhance endogenous insulin production by regeneration of the residual beta cells in insulin-dependent diabetes. Wouldn't this study imply that insulin-dependent diabetes is curable??

GS4, a water-soluble extract of the leaves of Gymnema sylvestre, was given to 27 patients with insulin-dependent diabetes on insulin therapy. They received 400 mg per day. Their insulin requirements came down together, along with their fasting blood glucose, HbA1c and glycosylated plasma protein levels. Patients in the study receiving insulin therapy only (without Gymnema sylvestre supplementation) showed no significant reduction in serum lipids, HbA1c or glycosylated plasma proteins when followed up after 10-12 months.

There you have it, folks. A study published in the Journal of Ethnopharmacologyin October 1990 says - there are possible ways to regenerate beta cells in insulin-dependent diabetics, previously believed to be nonexistent and gone forever. Never say never, right Dr. Faustman?

I know you've always wondered what a diabetes drug might do to a nondiabetic. Riddle solved for this drug- nothing. Dia-B Tech Limited, a Melbourne-based biotech, released results from a medical trial for a new treatment for type 2 diabetes that show it is safe for use in humans without diabetes.

The drug makes a patient's own insulin work better. The insulin sensitizing factor known as compound ISF402 attaches itself to insulin and helps break it down to a more useable form This is a great concept - and one that is fashioned fully in a bitter melon. However, let's give the Aussie biotech the spotlight. Bitter melon is not for the faint of heart - it has teeth!

The study included 24 healthy male volunteers given the treatment and it showed no adverse health effects. If it did not have any effect on healthy individuals - why call it a drug? Call it gum or something mundane. They may have to come up with a whole new category of drug that has no influence in healthy individuals. Maybe they should call it a biologically indifferent agent. Sounds like it still qualifies for a copay, right?

The company now plans to check the treatment's safety on 16 volunteers with type 2 diabetes. The company expects the safety trials to be completed mid-year and then plans to begin a larger trial to find out if the treatment works.